Key Insights

Highlights

Treatment Research

12 treatments under study, led by Cyclophosphamide

Related Conditions

Often studied with 14 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

3Total
Not Applicable (3)

Trial Status

Unknown2
Terminated1

Clinical Trials (3)

Showing 3 of 3 trials
NCT05532826Not ApplicableUnknown

Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT

NCT00006054Not ApplicableTerminated

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00006056Not ApplicableUnknown

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Showing all 3 trials

Research Network

Common Treatments

  • Cyclophosphamide2
  • Busulfan2
  • Etoposide2
  • Cyclosporine2
  • Antithymocyte Globulin2

Active Sponsors

  • Fairview University Medical Center2
  • Beijing Friendship Hospital1

Top Investigators

Related Conditions

  • Hemophagocytic Lymphohistiocytosis2
  • Xlinked Lymphoproliferative Syndrome2
  • Familial Erythrophagocytic Lymphohistiocytosis2
  • Chediakhigashi Syndrome2
  • Graft Versus Host Disease2

Activity Timeline